British journal of Cancer |
Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer |
juin. 16 |
|
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer |
Jan. 17 |
2 ♥ |
Cancer colorectal |
British journal of Cancer |
Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1 |
juil. 16 |
3 ♥ |
Cancers autres (hors CCR et CHC), Œsophage/Estomac |
British journal of Cancer |
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. |
fév. 18 |
2 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228) |
sep. 17 |
2 ♥ |
Cancer colorectal (CCR) |
British journal of Cancer |
Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma |
sep. 15 |
1 ♥ |
Carcinome hépatocellulaire (CHC), Foie |
British journal of Cancer |
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial |
avr. 19 |
1 ♥ |
Carcinome hépatocellulaire (CHC) |
British journal of Cancer |
The impact of age on complications, survival, and cause of death following colon cancer surgery |
Jan. 17 |
3 ♥ |
Cancer colorectal (CCR) |
British journal of Cancer |
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer |
sep. 16 |
2 ♥ |
Cancers autres (hors CCR et CHC), Pancréas/Voies biliaires |
British journal of Cancer |
A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases |
juin. 17 |
2 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours |
sep. 17 |
4 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma |
mai. 17 |
2 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. |
Jan. 18 |
3 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study |
Jan. 17 |
3 ♥ |
Cancer colorectal (CCR) |
British journal of Cancer |
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab |
juin. 17 |
1 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial |
oct. 17 |
3 ♥ |
Cancer colorectal (CCR) |
British journal of Cancer |
Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial |
mai. 17 |
2 ♥ |
Cancer colorectal (CCR) |
British journal of Cancer |
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients |
oct. 17 |
3 ♥ |
Cancers autres |
British journal of Cancer |
Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma |
juil. 18 |
|
Carcinome hépatocellulaire (CHC) |
British journal of Cancer |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data |
juin. 17 |
1 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity |
mai. 17 |
2 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib |
oct. 17 |
3 ♥ |
Cancers autres |
British journal of Cancer |
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin |
aoû. 18 |
1 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
Prediabetes and diabetes in relation to risk of gastric adenocarcinoma |
juin. 19 |
2 ♥ |
Cancers autres (hors CCR et CHC) |
British journal of Cancer |
GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project |
juin. 17 |
2 ♥ |
Cancer colorectal (CCR) |